High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy

被引:6
作者
Chen, Wei-Ming [1 ,2 ,3 ]
Wei, Kuo-Liang [1 ]
Tung, Shui-Yi [1 ]
Shen, Chien-Heng [1 ]
Chang, Te-Sheng [1 ,3 ]
Yen, Chih-Wei [1 ]
Hsieh, Yung-Yu [1 ]
Chiu, Wen Nan [4 ]
Hu, Jin Hung [4 ]
Lu, Sheng-Nan [1 ,5 ,6 ]
Hung, Chao-Hung [1 ,5 ,6 ]
机构
[1] Chiayi Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Chiayi, Taiwan
[2] Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr, Tainan, Taiwan
[3] Chang Gung Univ, Coll Med, Taoyuan, Taiwan
[4] Yulin Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Yuanlin, Taiwan
[5] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Kaohsiung, Taiwan
[6] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan
关键词
Glecaprevir/pibrentasvir; Hepatitis C virus; Sustained viral response; Virological failure; Pruritus; PIBRENTASVIR; GLECAPREVIR; HCV; LIVER; RISK;
D O I
10.1016/j.jfma.2020.08.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The real-world data of glecaprevir/pibrentasvir (GLE/PIB) therapy for patients with chronic hepatitis C virus (HCV) genotype 2 infection remained limited. We aimed to evaluate the possible predictors of virological failure and side effects of GLE/PIB therapy for chronic genotype 2 HCV-infected patients in a real-world setting. Methods: A total of 326 compensated HCV genotype 2 patients treated with GLE/PIB 12 weeks for cirrhotic patients (n Z 56) and 8 weeks for non-cirrhotic patients (n = 270) were enrolled. Results: The sustained virological response 12 weeks off therapy (SVR12) was 98.1%, 100%, and 97.7% in overall, GLE/PIB 12-week, and 8-week group, respectively. There were 6 (1.8%) patients with early withdrawal, and 14.1% patients had pruritus, the major adverse effect. In multivariate analyses, end-stage renal disease (odds ratio (OR) = 4.056, 95% confidence interval (CI) = 1.477-11.14, p = 0.007) and hypertension (OR = 2.325, 95% CI = 1.171-4.616, p = 0.016) were two significant factors associated with pruritus. There were 6 patients with virologic failure. In patients receiving 8-week GLE/PIB therapy, the SVR12 rate was significant lower in high baseline viral load (>= 10(7) IU/ml) group compared to low viral load group (90.6% v.s 98.7%, p = 0.025). Multivariate analyses showed that HCV RNA >= 10(7) IU/ml was one of the independent factors (OR = 0.134, 95% CI = 0.024-0.748; p = 0.022) associated with SVR12. Conclusion: GIE/PIB is an effective, tolerable and safe agent to treat genotype 2 HCV infected patients. However, high viral load (>= 10(7) IU/ml) may predict virologic failure in non-cirrhotic patients receiving 8 weeks GIE/PIB treatment. This result should be further validated in a large cohort in the future. Copyright (C) 2020, Formosan Medical Association. Published by Elsevier Taiwan LLC.
引用
收藏
页码:1593 / 1600
页数:8
相关论文
共 31 条
[1]   Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry [J].
Berg, Thomas ;
Naumann, Uwe ;
Stoehr, Albrecht ;
Sick, Christoph ;
John, Christine ;
Teuber, Gerlinde ;
Schiffelholz, Willibold ;
Mauss, Stefan ;
Lohmann, Kristina ;
Koenig, Bettina ;
Pangerl, Andreas ;
Niederau, Claus .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (08) :1052-1059
[2]   Glecaprevir/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial [J].
Brown, Robert S., Jr. ;
Buti, Maria ;
Rodrigues, Lino ;
Chulanov, Vladimir ;
Chuang, Wan-Long ;
Aguilar, Humberto ;
Horvath, Gabor ;
Zuckerman, Elimelech ;
Carrion, Barbara Rosado ;
Rodriguez-Perez, Federico ;
Urbanek, Petr ;
Abergel, Armand ;
Cohen, Eric ;
Lovell, Sandra S. ;
Schnell, Gretja ;
Lin, Chih-Wei ;
Zha, Jiuhong ;
Wang, Stanley ;
Trinh, Roger ;
Mensa, Federico J. ;
Burroughs, Margaret ;
Felizarta, Franco .
JOURNAL OF HEPATOLOGY, 2020, 72 (03) :441-449
[3]   Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study [J].
Carrat, Fabrice ;
Fontaine, Helene ;
Dorival, Celine ;
Simony, Melanie ;
Diallo, Alpha ;
Hezode, Christophe ;
De Ledinghen, Victor ;
Larrey, Dominique ;
Haour, Georges ;
Bronowicki, Jean-Pierre ;
Zoulim, Fabien ;
Asselah, Tarik ;
Marcellin, Patrick ;
Thabut, Dominique ;
Leroy, Vincent ;
Tran, Albert ;
Habersetzer, Francois ;
Samuel, Didier ;
Guyader, Dominique ;
Chazouilleres, Olivier ;
Mathurin, Philippe ;
Metivier, Sophie ;
Alric, Laurent ;
Riachi, Ghassan ;
Gournay, Jerome ;
Abergel, Armand ;
Cales, Paul ;
Ganne, Nathalie ;
Loustaud-Ratti, Veronique ;
D'Alteroche, Louis ;
Causse, Xavier ;
Geist, Claire ;
Minello, Anne ;
Rosa, Isabelle ;
Gelu-Simeon, Moana ;
Portal, Isabelle ;
Raffi, Francois ;
Bourliere, Marc ;
Pol, Stanislas ;
Bonnet, Delphine ;
Payssan-Sicart, Virginie ;
Pomes, Chloe ;
Bailly, Francois ;
Beaudoin, Marjolaine ;
Giboz, Dominique ;
Hartig-Lavie, Kerstin ;
Maynard, Marianne ;
Billaud, Eric ;
Boutoille, David ;
Cavellec, Morane .
LANCET, 2019, 393 (10179) :1453-1464
[4]   Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis [J].
Chen, Chun-Hsien ;
Chen, Chien-Hung ;
Lin, Chih-Lang ;
Lin, Chun-Yen ;
Hu, Tsung-Hui ;
Tung, Shui-Yi ;
Hsieh, Sen-Yung ;
Lu, Sheng-Nan ;
Chien, Rong-Nan ;
Hung, Chao-Hung ;
Sheen, I-Shyan .
SCIENTIFIC REPORTS, 2019, 9 (1)
[5]   Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C [J].
D'Ambrosio, Roberta ;
Pasulo, Luisa ;
Puoti, Massimo ;
Vinci, Maria ;
Schiavini, Monica ;
Lazzaroni, Sergio ;
Soria, Alessandro ;
Gatti, Federico ;
Menzaghi, Barbara ;
Aghemo, Alessio ;
Capelli, Francesca ;
Rumi, Maria Grazia ;
Morini, Lorenzo ;
Giorgini, Alessia ;
Pigozzi, Marie Graciella ;
Rossini, Angelo ;
Maggiolo, Franco ;
Pan, Angelo ;
Memoli, Massimo ;
Spinelli, Ombretta ;
Del Poggio, Paolo ;
Saladino, Valeria ;
Spinetti, Angiola ;
De Bona, Anna ;
Capretti, Andrea ;
Uberti-Foppa, Caterina ;
Bonfanti, Paolo ;
Terreni, Natalia ;
Menozzi, Fernanda ;
Colombo, Alberto Eraldo ;
Giglio, Omar ;
Centenaro, Riccardo ;
Borghi, Marta ;
Baiguera, Chiara ;
Picciotto, Viviana ;
Landonio, Simona ;
Gori, Andrea ;
Magnani, Carlo ;
Noventa, Franco ;
Paolucci, Stefania ;
Lampertico, Pietro ;
Fagiuoli, Stefano .
JOURNAL OF HEPATOLOGY, 2019, 70 (03) :379-387
[6]   EASL Recommendations on Treatment of Hepatitis C 2018 [J].
Pawlotsky J.-M. ;
Negro F. ;
Aghemo A. ;
Berenguer M. ;
Dalgard O. ;
Dusheiko G. ;
Marra F. ;
Puoti M. ;
Wedemeyer H. .
JOURNAL OF HEPATOLOGY, 2018, 69 (02) :461-511
[7]  
Falade-Nwulia O, 2017, ANN INTERN MED, V166, P637, DOI [10.7326/M16-2575, 10.7326/m16-2575]
[8]   Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial [J].
Forns, Xavier ;
Lee, Samuel S. ;
Valdes, Joaquin ;
Lens, Sabela ;
Ghalib, Reem ;
Aguilar, Humberto ;
Felizarta, Franco ;
Hassanein, Tarek ;
Hinrichsen, Holger ;
Rincon, Diego ;
Morillas, Rosa ;
Zeuzem, Stefan ;
Horsmans, Yves ;
Nelson, David R. ;
Yu, Yao ;
Krishnan, Preethi ;
Lin, Chih-Wei ;
Kort, Jens J. ;
Mensa, Federico J. .
LANCET INFECTIOUS DISEASES, 2017, 17 (10) :1062-1068
[9]   Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis [J].
Friedrich-Rust, M. ;
Nierhoff, J. ;
Lupsor, M. ;
Sporea, I. ;
Fierbinteanu-Braticevici, C. ;
Strobel, D. ;
Takahashi, H. ;
Yoneda, M. ;
Suda, T. ;
Zeuzem, S. ;
Herrmann, E. .
JOURNAL OF VIRAL HEPATITIS, 2012, 19 (02) :E212-E219
[10]   Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment [J].
Gane, Edward ;
Lawitz, Eric ;
Pugatch, David ;
Papatheodoridis, Georgios ;
Brau, Norbert ;
Brown, Ashley ;
Pol, Stanislas ;
Leroy, Vincent ;
Persico, Marcello ;
Moreno, Christophe ;
Colombo, Massimo ;
Yoshida, Eric M. ;
Nelson, David R. ;
Collins, Christine ;
Lei, Yang ;
Kosloski, Matthew ;
Mensa, Federico J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (15) :1448-1455